Anti BCMA chimeric antigen receptor T cell therapy - Chongqing Precision Biotech
Alternative Names: BCMA CAR-T cells - Chongqing Precision Biotech Co LtdLatest Information Update: 03 Mar 2021
At a glance
- Originator Chongqing Precision Biotech Co., Ltd
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 01 Jan 2021 Chongqing Precision Biotech initiates a phase I/II trial in Multiple myeloma (In adults, In the elderly, Second-line therapy or greater) in China (IV, Infusion) (NCT04776330)
- 01 Dec 2019 Chongqing Precision Biotech initiates a phase I/II trial in Multiple myeloma (In adults, In the elderly, Second-line therapy or greater) in China (IV, Infusion) (NCT04272151)